Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease

Ann Intern Med. 2006 Mar 7;144(5):I29. doi: 10.7326/0003-4819-144-5-200603070-00003.
No abstract available

Publication types

  • Patient Education Handout

MeSH terms

  • Aspirin / adverse effects
  • Aspirin / economics*
  • Aspirin / therapeutic use*
  • Computer Simulation
  • Coronary Disease / prevention & control*
  • Cost-Benefit Analysis
  • Drug Costs
  • Drug Therapy, Combination
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / economics*
  • Fibrinolytic Agents / therapeutic use*
  • Gastrointestinal Hemorrhage / chemically induced
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Markov Chains
  • Middle Aged
  • Primary Prevention
  • Quality-Adjusted Life Years
  • Risk Factors
  • Sensitivity and Specificity
  • Stroke / chemically induced

Substances

  • Fibrinolytic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Aspirin